The DOI matches its Crossref record.
The effects of the human MDR1 genotype on the expression of duodenal P‐glycoprotein and disposition of the probe drug talinolol
Abstract
Background and objectives: A single‐nucleotide polymorphism (SNP) of the human multidrug‐resistance gene in wobble position of exon 26 reportedly predicts expression and function of P‐glycoprotein in human enterocytes and lymphocytes. Several other allelic variants of MDR1 have been identified, some of which lead to amino acid exchange with as yet unknown functional relevance. Methods: In healthy white volunteers, we investigated the influence of the hereditary variants C3435T in exon 26 and G2677T/A (Ala893Ser/Thr) in exon 21 and the influence of 7 frequent or putative functional SNPs on duodenal MDR1 messenger ribonucleic acid (n = 32) and immunoreactive P‐glycoprotein (n = 37) expression. Moreover, the disposition of the probe drug talinolol was evaluated in 55 subjects after oral administration (100 mg) and in 23 subjects after intravenous administration(30 mg). Results: Duodenal MDR1 messenger ribonucleic acid and P‐glycoprotein, as assessed by real‐time polymerase chain reaction (Taq Man) and immunostaining, were not influenced by any MDR1 polymorphism studied. Talinolol disposition was not affected by the exon 26 mutation C3435T. In carriers of the TT/TA variants of G2677T/A, the area under the serum concentration‐time curve values of oral talinolol were slightly but significantly elevated compared with those in carriers of at least 1 wild‐type allele (P < .05, Kruskal‐Wallis test; P = .014, Mann‐Whitney U test). However, multiple comparisons with combinations of putative functional SNPs did not confirm a significant influence of the MDR1 genotype on talinolol disposition. Conclusions: We did not identify any influence of MDR1 genotypes on duodenal expression of P‐glycoprotein and disposition of talinolol in humans. Clinical Pharmacology & Therapeutics (2002) 72, 572–583; doi: 10.1067/mcp.2002.127739
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance
Marzolini, C. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.09.012 · Cited by 895
Drug-Resistant Epilepsy: Multiple Hypotheses, Few Answers
Tang, F., Hartz, A. M. S., & Bauer, B. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00301 · Cited by 482
Choudhuri, S., & Klaassen, C. D. (2006) · International Journal of Toxicology · doi:10.1080/10915810600746023 · Cited by 415
Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine
Ahmed, S., Zhou, Z., Zhou, J., & Chen, S.-Q. (2016) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2016.03.008 · Cited by 371
Expression and function of efflux drug transporters in the intestine
Takano, M., Yumoto, R., & Murakami, T. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.06.005 · Cited by 356
Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs
Cascorbi, I. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.04.009 · Cited by 355
Self-citationStaatz, C. E., Goodman, L. K., & Tett, S. E. (2010) · Clinical Pharmacokinetics · doi:10.2165/11317550-000000000-00000 · Cited by 343
Chemotherapy-induced resistance by ATP-binding cassette transporter genes
GILLET, J., EFFERTH, T., & REMACLE, J. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.05.002 · Cited by 337
Staatz, C. E., Goodman, L. K., & Tett, S. E. (2010) · Clinical Pharmacokinetics · doi:10.2165/11317350-000000000-00000 · Cited by 336
Somogyi, A. A., Barratt, D. T., & Coller, J. K. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100095 · Cited by 324
Wolking, S., Schaeffeler, E., Lerche, H., Schwab, M., & Nies, A. T. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0267-1 · Cited by 309
Leschziner, G. D., Andrew, T., Pirmohamed, M., & Johnson, M. R. (2007) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500413 · Cited by 300
Potential Role of Drug Transporters in the Pathogenesis of Medically Intractable Epilepsy
Kwan, P., & Brodie, M. J. (2005) · Epilepsia · doi:10.1111/j.0013-9580.2005.31904.x · Cited by 281
Anglicheau, D., Verstuyft, C. A. A., Laurent-Puig, P., Becquemont, L., Schlageter, M.-H. A. A. G. A., Cassinat, B., Beaune, P., Legendre, C., & Thervet, E. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000073901.94759.36 · Cited by 281
Haas, D. W., Smeaton, L. M., Shafer, R. W., Robbins, G. K., Morse, G. D., Labbé, L., Wilkinson, G. R., Clifford, D. B., D’Aquila, R. T., De Gruttola, V., et al. (2005) · The Journal of Infectious Diseases · doi:10.1086/497610 · Cited by 257
L??tsch, J., Skarke, C., Liefhold, J., & Geisslinger, G. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443140-00003 · Cited by 256
Pharmacogenetics‐Based New Therapeutic Concepts
Roots, I., Gerloff, T., Meisel, C., Kirchheiner, J., Goldammer, M., Kaiser, R., Laschinski, G., Brockmöller, J., Cascorbi, I., Kleeberg, U., et al. (2004) · Drug Metabolism Reviews · doi:10.1081/dmr-200033458 · Cited by 33
Self-citation
Metadata
- Authors
- Siegmund, W., Ludwig, K., Giessmann, T., Dazert, P., Schroeder, E., Sperker, B., Warzok, R., Kroemer, H. K., & Cascorbi, I.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2002-11
- Volume
- 72
- Issue
- 5
- Pages
- 572-583
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2002345475
- Cited by
- 199
- References
- 0
- FWCI
- 7.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.